

1 **Title: Clonal haematopoiesis is associated with major adverse cardiovascular events in**
2 **patients with hypertrophic cardiomyopathy.**

3 **Brief Title: Clonal haematopoiesis affects outcomes in HCM patients.**

4 Fernando L. Scolari MD PhD^{a,b,c}, Darshan Brahmabhatt MBBChir MD(Res)^{a,b,d}, Sagi Abelson PhD^{e,f}
5 Deacon Lee MB ChB^a, Raymond H Kim MD PhD^{b,e,h,j}, Ali Pedarzadeh MD^a, Ali Sakhnini MD^a,
6 Arnon Adler MD MSc^a, Raymond H Chan MD MPH^{a,g}, John Dick PhD^{f,h}, Harry Rakowski MD^a and
7 Filio Billia MD PhD^{a,b,c*}

8 **Affiliations:**

- 9 a. Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada
10 b. Ted Rogers Centre for Heart Research, Toronto, ON, Canada
11 c. Toronto General Hospital Research Institute, Toronto, ON, Canada
12 d. Mount Sinai Hospital, Toronto, ON, Canada
13 e. Ontario Institute for Cancer Research, Toronto, ON, Canada
14 f. Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada
15 g. Institute for Clinical Evaluation Sciences, Toronto ON, Canada
16 h. Princess Margaret Cancer Centre, Toronto, ON, Canada
17 j. Division of Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, ON, Canada
18

19 *** Corresponding Author:**

20 Dr. Filio Billia MD PhD
21 585 University Ave., 6EN-242
22 Toronto Ontario M5G 2N2
23 416-340-4800 x 6805
24 416-340-4012 (fax)
25 Email: Phyllis.billia@uhn.ca
26

27 Twitter: @FilioBillia @Scolari_Fernand @Doctor_Darshan

28 Tweet: Clonal haematopoiesis confers a higher risk of adverse outcomes in patients with
29 hypertrophic cardiomyopathy and sarcomeric gene mutation, including higher degree of
30 fibrosis and major adverse cardiovascular events.

31 Hashtags: #HCM; #CHinHCM; #

32 Word count (not including title, abstract, acknowledgment, references, tables, and figure
33 legends): 2977

34 Funding: This work was supported by the Peter Munk Cardiac Centre Innovation Fund.

35 Disclosures: FB receives grant funding from Abbott Laboratories, Canadian Institutes for Health
36 Research. AA is a Consultant for Bristol-Myers-Squibb.

37

38 **KEY POINTS**

39 **Question:** Does clonal haematopoiesis (CH) affect the phenotype and outcomes among
40 hypertrophic cardiomyopathy (HCM) patients?

41 **Findings:** Among 799 patients, CH was found in 183 (22.9%) HCM patients. CH was associated
42 with symptoms, a higher burden of fibrosis and major cardiovascular events. Several cytokines
43 and troponin I were upregulated in gene-positive HCM patients with CH.

44 **Meaning:** CH helps to identify those HCM patients at risk for serious adverse events and unveils
45 a potential inflammatory response mechanism that affects prognosis.

46

47

48

49

50

51

52

53

54

55

56 **ABSTRACT**

57 **Background & Aims:** The heterogeneous phenotype of hypertrophic cardiomyopathy (HCM) is
58 still not fully understood. Clonal haematopoiesis (CH) is emerging as a cardiovascular risk factor
59 potentially associated with adverse clinical events. The prevalence, phenotype and outcomes
60 related to CH in HCM patients was evaluated.

61 **Methods:** Patients with HCM and available biospecimens from the Peter Munk Cardiac Centre
62 Cardiovascular Biobank were subjected to targeted sequencing for 35 myeloid genes associated
63 with CH. CH prevalence, clinical characteristics, morphological phenotypes assessed by
64 echocardiogram and cardiac magnetic resonance and outcomes were assessed. All patients
65 were evaluated for a 71-plex cytokines/chemokines, troponin I and B-type natriuretic peptide
66 analysis. Major cardiovascular events (MACE) were defined as appropriate ICD shock, stroke,
67 cardiac arrest, orthotopic heart transplant and death.

68 **Results:** Among the 799 patients, CH was found in 183 (22.9%) HCM patients with sarcomeric
69 germline mutations. HCM patients with CH were more symptomatic and with a higher burden
70 of fibrosis than those without CH. CH was associated with MACE in those HCM patients with
71 sarcomeric germline mutations [adjusted HR of 3.46 (95% CI 1.25-9.52; p=0.016)], with the
72 highest risk among those that had *DNMT3A*, *TET2* and *ASXL1* mutations [adjusted HR of 7.23
73 (95% CI 1.79-29.13) p=0.005]. Several cytokines (IL-1ra, IL-6, IL-17F, TGFa, CCL21, CCL1, CCL8,
74 and CCL17), and troponin I were upregulated in gene-positive HCM patients with CH.

75 **Conclusions:** These results indicate that CH in patients with HCM is associated with worse
76 clinical outcomes. In the absence of CH, gene-positive patients with HCM have lower rates of
77 MACE.

78 **Introduction**

79 Hypertrophic cardiomyopathy (HCM) is an inherited cardiovascular disorder, affecting 1 in 500
80 individuals.¹ However, germline pathogenic or likely pathogenic (P/LP) genetic variants, such as
81 *MYH7* and *MYBPC3* genes, are identified in only 25-40% of patients.^{2,3} A wide heterogeneity
82 and distinct morphologies of left ventricular (LV) hypertrophy are described, even amongst
83 family members carrying similar genetic variants.^{1,2,4-7} Interestingly, interstitial fibrosis is
84 detected in 40-70% of patients and is associated with sudden cardiac death (SCD). Although
85 HCM can be well tolerated, a subset of patients may require advanced treatments such as
86 orthotopic heart transplant (OHT) and LV assist devices.^{3,8}

87 The underlying mechanisms involved in the heterogeneous clinical presentation of HCM
88 patients are not well understood.^{3,8} Clonal haematopoiesis (CH) has emerged as a new risk
89 factor for the development of atherosclerosis, heart failure and cardiogenic shock and is
90 associated with worse outcomes.⁹⁻¹³ With aging, haematopoietic stem cells acquire somatic
91 mutations in genes regulating epigenetic DNA modifications and other pathways resulting in
92 clonal expansion. Experiments have shown that CH mutation may promote LV remodelling and
93 fibrosis through increased inflammation.¹⁴⁻¹⁷ Interestingly, a proteomic study has also shown
94 activation of inflammatory pathways in HCM.^{18,19} The role of CH driving inflammatory processes
95 that may lead to adverse clinical events in individuals with HCM is unknown. Therefore, we
96 sought to evaluate the prevalence of CH in a large HCM cohort and define its association with
97 phenotype and outcomes.

98 **METHODS**

99 **Patient selection**

100 This is a retrospective study to evaluate the association of CH in a cohort of patients with HCM.
101 We screened 4,400 patients from the HCM clinic of the Toronto General Hospital (Ontario,
102 Canada) from January 2001 to January 2022. We included 799 patients who were ≥ 18 years of
103 age, with a clinical diagnosis of HCM by current guidelines^{2,19}, cardiac magnetic resonance
104 imaging (MRI) and available biospecimens from the Peter Munk Cardiac Centre Cardiovascular
105 Biobank. All patients were systematically approached for biobanking. We excluded patients
106 with incomplete records, those that withdraw consent, or low biospecimen quality. This study
107 was approved by the UHN Research Ethics Board (#21-5313) and complied with the Declaration
108 of Helsinki.

109

110 **Definitions**

111 HCM was defined as the presence of maximal LV wall thickness (MLVWT) ≥ 15 mm, ≥ 13 mm in
112 the presence of a P/LP genetic variant or a family history of HCM, in the absence of other
113 causes. The assessment of P/LP variants was conducted using a previously published strategy by
114 our group²⁰. All patients with HCM underwent cardiac MRI with late gadolinium enhancement
115 (LGE) for fibrosis quantification. The LGE was assessed visually and quantified manually as
116 previously validated.⁷ LGE extent was defined as the LGE mass percentage of the total LV mass.
117 We were able to quantify LGE in (84.1%) of patients. In the remaining 127 (15.9%) patients, we
118 only included the qualitative measure of LGE.

119 **Data collection, outcomes and follow-up**

120 Clinical data were collected from a digital de-identified database. All collected data, including
121 echocardiogram and cardiac MRI, were the closest to the time of biospecimen collection. The
122 following outcomes were collected: appropriate implantable cardioverter defibrillator shock,
123 stroke, cardiac arrest, OHT and death.²¹ We also condensed these as major cardiovascular
124 events (MACE) defined as the first occurrence of any. Only outcomes occurring after sample
125 collection were included. Patients were followed from the time of biospecimen collection to the
126 last visit to our institution. Loss to follow-up was defined as no interaction with the patient at
127 our institution in the preceding one year from chart assessment.

128

129 **Clonal haematopoiesis and cytokine assessment**

130 All peripheral blood biospecimens were collected during routine visits to the HCM clinic with
131 consent. For all patients, the biospecimen closest to the cardiac MRI assessment was selected.
132 Briefly, the cytokine analysis was performed using a human cytokine/chemokine 71-plex assay
133 with the Luminex™ 200 system by Eve Technologies Corp. (Alberta, Canada). In addition, the
134 levels of B-type natriuretic peptide and cardiac troponin I were evaluated. For CH genetic
135 analysis, a single molecule molecular inversion probe method targeting 35 myeloid genes
136 related to CH was implemented as previously described^{9,22}. To call mutations we used SmMIP-
137 tools²⁶. CH was considered in those patients with variants with a VAF $\geq 2\%$. Additional details
138 are provided in the Supplementary materials.

139

140 **Statistical analysis**

141 The complete statistical methods are shown in the Supplementary materials. Continuous data
142 were evaluated for normality with Shapiro-Wilk test and histogram analysis and presented as
143 mean \pm standard deviation or median (interquartile range). Categorical variables were
144 presented as total count (frequency). A Student's T test or Mann-Whitney test was used to
145 compare continuous variables according to normal distribution. ANOVA and Chi-square test (or
146 Fisher's exact test) were used for comparing groups. Survival analysis was conducted using the
147 Kaplan-Meier method and differences assessed with the log-rank test. Cox proportional hazards
148 regressions were employed to compare survival rates, adjusting for age as a covariate. A
149 propensity score matching was used to address possible confounders according to CH. As a
150 sensitivity analysis, we also tested those with CH only in the three most common CH genes
151 (*DNMT3A*, *TET2* and *ASXL1*). We used a statistical significance of 0.05 for all analyses and a two-
152 sided p-value. All analyses were performed using SPSS, version 25.0 (SPSS Inc., NY, USA).

153 **Results**

154 We included 799 patients in the study and the overall characteristics of the cohort are
155 summarized in Table 1. Briefly, the mean age of our cohort was 55.7 ± 14.6 years, 547 patients
156 (68.5%) were males, with an age at the time of HCM diagnosis of 47.8 ± 15.8 years. Germline
157 genetic testing was performed on 712 (89.1%) patients, with a P/LP variant identified in 206
158 (25.8%) patients. P/LP variants were primarily in *MYBPC3* (127, 61.6%) and *MYH7* (53, 25.7%).
159 Mean MLVWT was 17.1 ± 4.2 mm, whereas 170 (21.3%) patients exhibited a LV outflow tract
160 maximal gradient ≥ 50 mmHg. The median time from biospecimen collection to the
161 echocardiogram was 0 (0-16) days and median time from biospecimen to MRI assessment was
162 2.2 (0.2-5.6) years.

163

164 **Clonal haematopoiesis prevalence and characteristics**

165 All patients had an assessment of CH and all samples passed quality control specifications. CH
166 mutations were observed in 183 (22.9%) patients with a median variant allele (VAF) frequency
167 of 6.7% (2.8-40.8). Of these patients, 136 (17.0%) had somatic mutations in the three most
168 common CH genes: *DNMT3A* in 70 (8.8%), *TET2* in 51 (6.3%), and *ASXL1* in 24 (3.0%), comprising
169 73.8% of all CH mutations (Figure 1A). The CH-associated gene mutations summary is shown in
170 Supplementary Table 1. Most patients (158, 19.8%) harboured a single mutation and of the 183
171 patients with CH (Figure 1B), 135 (73.7%) were >50 years old (Figure 1C). In relation to the HCM
172 diagnosis age, the majority, 94 (51.3%), were diagnosed after 50 years old.

173 Overall, clinical characteristics of CH patients were similar to those without CH (Table 1). There
174 was no statistical difference regarding age, age at HCM diagnosis, and comorbidities according
175 to CH status. Both groups underwent genetic testing equally. Family history of SCD was more
176 common among CH patients [11 (6%) vs. 26 (4.2%), $p=0.048$]. CH patients were more likely to
177 have a pacemaker implantation, [7 (3.8%) vs. 6 (1.0%), $p=0.007$] and to be treated with non-
178 dihydropyridine calcium channel blockers [39 (21.3%) vs. 77 (12.5%), $p=0.003$].

179 No differences were found in echocardiographic or cardiac MRI parameters, or other HCM
180 features such as syncope or abnormal blood pressure response (ABPR) at exercise according to
181 CH (Supplementary Table 2). However, the presence of an apical aneurysm [33 (5.4%) vs. 14
182 (7.7%), $p=0.004$] and death or need for OHT were higher among HCM patients with CH [6 (3.3%)
183 vs. 4 (0.6%), $p=0.005$]. MACE was also more frequent among patients with CH [12 (2.0%) vs. 9
184 (5.2%), $p=0.026$], with an unadjusted HR of 2.72 (95% CI 1.14-6.49; $p=0.023$), and adjusted HR
185 of 3.46 (95% CI 1.25-9.52; $p=0.016$). CH patients showed a worse survival in comparison to
186 those without CH as shown in the Kaplan-Meier curve (Log-Rank $P=0.018$) (Figure 2A).

187

188 **Clonal haematopoiesis related to *DNMT3A*, *TET2* and *ASXL1***

189 Since *DNMT3A*, *TET2* and *ASXL1* are the most frequent and more lethal CH-associated gene
190 mutations⁹, we performed a sub-analysis including these 3 genes and comparing to patients
191 without CH in other genes. Patients harbouring *DNMT3A*, *TET2* and *ASXL1* mutations were older
192 than their counterparts [58.1 ± 14.5 vs. 55.3 ± 14.6 , $p=0.046$] and more likely to have a family
193 history of SCD [9 (6.7%) vs 26 (4.2%), $p=0.035$]. As we note in the broader CH analysis, these

194 patients were more likely to have hypertension, a P/LP HCM germline variant, a pacemaker and
195 treated with a non-dihydropyridine calcium channel blocker (Supplementary Table 3).

196 While patients with *DNMT3A*, *TET2* and *ASXL1* CH mutations exhibited a similar HCM
197 phenotype to those without CH (Supplementary Table 4), patients with CH showed a higher
198 mortality or need for OHT [6 (4.4%) vs. 4 (0.6%), $p < 0.0001$] and MACE [8 (6.2%) vs. 12 (2.0%),
199 $p = 0.008$]. The unadjusted HR for MACE was 3.25 (95% CI 1.32-7.98; $p = 0.010$) and adjusted HR
200 3.34 (95% CI 1.33-8.42; $p = 0.010$). Figure 2B shows the Kaplan-Meier curve with worse survival
201 for patients with CH (Log-Rank $p = 0.006$).

202

203 **Clonal haematopoiesis in HCM patients with germline sarcomeric gene P/LP variant**

204 HCM patients harbouring a germline sarcomeric P/LP variant are associated with early age at
205 diagnosis, higher MLVWT and worse outcomes.²³ In our cohort, patients with a germline
206 sarcomeric P/LP variant were associated with worse MACE (HR 3.1, 95% CI 1.17-8.49, $p = 0.022$).
207 As this subtype of HCM patients have a distinct clinical profile and are less likely to be
208 phenocopies, we sought to investigate the CH effect in this subset of patients. Only patients
209 with genetic screening were included [N=680 (85.1%)]. Clinical characteristics and outcomes are
210 summarized in Supplementary Table 5 and in Table 2 respectively. Those with CH mutations
211 showed a trend towards a higher burden of symptoms (NYHA class II to IV) [15 (40.5%) vs. 47
212 (28.0%), $p = 0.132$]. CH was also associated with a higher burden of fibrosis as reflected by LGE in
213 $>15\%$ of the LV mass [11 (29.7%) versus 26 (15.3%), $p = 0.044$], with an odds ratio of 2.32 (95% CI
214 1.00-5.38, $p = 0.048$). A trend towards a higher degree of fibrosis in those patients with CH was

215 also observed [15.6 % (10.4-24.6) vs. 12.2 % (7.7-17.6), p=0.068]. CH patients did show a higher
216 frequency of ABPR at exercise [10 (62.5%) vs. 25 (29.8%), p=0.012]. Finally, CH was associated
217 with greater mortality or need for OHT [3 (8.1%) vs. 2 (1.2%), (p=0.013)] and MACE [5 (13.5%)
218 vs. 5 (3.0%), p=0.008], with an unadjusted HR of 5.28 (95% CI 1.51-18.4, p=0.009), and adjusted
219 HR of 6.89 (95% CI 1.78-26.6, p=0.005). Figure 2C shows the Kaplan-Meier survival curve
220 showing a worse survival for those with CH (log-rank p=0.003).

221 We then evaluated the HCM phenotype and clinical outcomes in those with germline
222 sarcomeric genes P/LP variants according to *DNMT3A*, *TET2*, and *ASXL1* CH mutations. Baseline
223 characteristics were similar between groups (Supplementary Table 6). The amount of fibrosis
224 assessed by LGE was higher in those with CH [21.2% (13.7-41.8) vs. 12.2% (7.7-17.6), p=0.017].
225 CH patients showed a higher frequency of ABPR with exercise than those without CH [8 (66.7%)
226 vs. 25 (29.8%), p=0.012]. Mortality or OHT was more common in the CH group than in those
227 without CH [3 (13.0%) vs. 2 (1.2%), p<0.0001], as well as MACE [4 (17.4%) vs. 5 (3.0%), p=0.003].
228 MACE was associated with CH with an unadjusted HR of 5.28 [(95%CI 1.51-18.41) p=0.009] and
229 for the specific *DNMT3A*, *TET2* and *ASXL1* CH-mutated genes had a HR of 5.76 [(95%CI 1.51-
230 21.94), p=0.010]. Figure 2C and 2D shows the Kaplan-Meier survival curve showing a worse
231 survival for those with CH and by specific CH mutations, respectively (log-rank p=0.007).

232

233 **Propensity score matched analysis**

234 A propensity score matching was performed to address potential confounding factors. The
235 group balance is shown in the Supplementary material. After the matching procedure, 514

236 patients without CH and 183 with CH were selected. Clinical characteristics, the HCM
237 phenotype and outcomes are shown in Supplementary tables 7 and 8, respectively. CH was
238 associated with MACE with an unadjusted HR of 2.78 (95% CI 1.15-6.72; p=0.023) and an
239 adjusted HR of 2.47 (95% CI 1.01-6.02; p=0.046). We then performed a subgroup analysis
240 according to CH and genotype. Patients with CH and germline P/LP variants were associated
241 with higher MACE with an unadjusted HR of 11.3 (95% CI 3.28-39.4; p<0.0001) and an adjusted
242 HR of 12.0 (95% CI 3.4-41.8; p<0.0001). Similar results were observed testing for specific CH
243 mutations (*DNMT3A*, *TET2* and *ASXL1*) with a HR of 6.06 (95%CI 1.47-24.94; p=0.013) and with
244 an adjusted HR of 7.31 (94% CI 1.66-32.09; p=0.008). The central figure shows the Kaplan-Meier
245 survival curve and the forest plot for HR according to these subgroups.

246

247 **Biomarkers and cytokines/chemokines**

248 A panel of 71 cytokines and chemokines, B-type natriuretic peptide and cardiac troponin I were
249 evaluated in patients with a germline sarcomeric P/LP variant and levels were compared among
250 those with (N=37) or without CH (N=169) (Figure 3). We observed significant elevated
251 circulating levels of troponin I, IL-1ra, IL-6, IL-17F, TGF α , CCL21, CCL1, CCL8, and CCL17 in
252 patients with CH. We then sought to investigate if specific CH mutations were associated with
253 specific cytokines/chemokines. In HCM patients with germline P/LP sarcomeric variants, those
254 with CH due to *DNMT3A* (N=16) mutations showed higher levels of IL-9 and CXCL12. *TET2* CH
255 carriers (N=6) showed higher levels of troponin I, IL-5, IL-10, CXCL10, CXCL9, CCL4, VEGF-A,
256 CCL21, CXCL13 and CCL1. Cytokines, chemokines, troponin I and B-type natriuretic peptide

257 results among HCM patients with a germline P/LP sarcomeric variant and with or without CH is
258 shown in Supplementary Table 9.

259

260 Discussion

261 The heterogeneity in HCM patients arises from mutations interacting with genetic and
262 nongenetic factors.²⁴ Our study found a higher CH prevalence in HCM patients, linked to more
263 symptoms, ABPR during exercise, fibrosis and MACE. In addition, there were differential levels
264 of circulating cytokines/chemokines and troponin in HCM patients with CH, highlighting a
265 potential causal mechanism between the phenotype and outcomes. This is the first description
266 of an association between CH prevalence, HCM phenotype and clinical outcomes.

267 Population studies have shown that CH prevalence ranges between 0-29% and increases with
268 age.¹¹ However, CH prevalence depends on assay sensitivity, VAF cut-off and the selected
269 population of interest.^{11,25,26} In the present study, we found that 22.9% of HCM patients
270 harboured CH mutations. Although most CH mutations were found in those >50 years, 25.9% of
271 the patients <30 years also had CH in our study. Interestingly, somatic mutations in
272 haematopoietic stem cells occurring in the first decades of life are polyclonal and have
273 unknown long-term effects.^{27,28}

274 Many studies have focused on the most common gene variants, such as *DNMT3A*, *TET2* and
275 *ASXL1*^{9,12,22,26,29}, present in 17% of HCM patients with CH mutations. Unsurprisingly, we found
276 that HCM patients with these specific genes showed worse clinical phenotype and outcome,
277 similarly to other patient cohorts.^{9,12,26,29} Experiments have shown that CH mediated by these
278 genes were also associated with LV remodelling and interstitial fibrosis^{14,16,30-32}, with evidence
279 of macrophages migrating to the myocardium and enhancing systemic inflammation.^{15,16}

280 HCM is characterized by asymmetric LV hypertrophy accompanied by LV outflow tract
281 obstruction and myocardial fibrosis.¹ While the CH impact on HCM was never explored in
282 animal models, we observed that MLVWT was not affected by CH, even when restricting to
283 gene-positive HCM patients. The HCM expression occurring before the acquisition of CH
284 mutations may explain this lack of association.

285 Fibrosis was more common in patients with HCM who have a sarcomeric P/LP variant and
286 *DNMT3A*, *TET2* and *ASXL1* somatic mutations. These patients also exhibited higher levels of
287 inflammatory cytokines/chemokines, potentially contributing to increased fibrosis. This is an
288 important finding as fibrosis is linked to SCD in patients with HCM.³³ In addition, ABPR at
289 exercise, a prognostic marker in HCM³⁴, was also more frequent among those with CH and HCM
290 with sarcomeric germline P/LP variants. This result potentially illustrates that CH could affect
291 the HCM phenotype and promote adverse outcomes. Thus, these observations may reflect a ‘2-
292 hit’ sequence of events with the first hit being the germline P/LP sarcomeric mutation followed
293 by the second hit driven by CH.

294 In this study, we showed that, in subsets of HCM patients, the mortality or need for OHT is
295 increased among CH patients even when adjusting for confounding factors, being in
296 consonance with prior studies.^{9,12,22,26,29,35} In addition, a higher CH associated risk was observed
297 in those with sarcomeric P/LP variants and/or specific CH genes. Our results do not address the
298 specific CH mechanisms involved, but we hypothesize that epigenetic aging and the
299 inflammatory milieu may drive these outcomes.

300 The increased inflammatory pathways recently shown in HCM^{18,36} associated with higher levels
301 of circulating inflammatory cytokines/chemokines in CH,^{9,15,16} may have a role in driving worse
302 outcomes. In fact, we observed higher circulating levels of several inflammatory cytokines,
303 chemokines, and troponin I among those with CH. However, specific CH mutations may have
304 distinct inflammatory profiles.^{9,22} We observed that *DNMT3A*-driven CH was associated with IL-
305 9 and CXCL12. *TET2*-driven CH was associated with the higher circulating levels of a different
306 array of cytokines/chemokines including troponin I. Our own previous work has shown that
307 *TET2*-driven CH have been associated with a higher inflammatory milieu and a higher lethality,
308 not seen with *DNMT3A*.^{9,16,25,30}

309

310 **Limitations**

311 There are several limitations that should be considered. Despite minimal biospecimen-to-
312 echocardiogram timing, CH evaluation to MRI time varied (median 2.2 years, range <1 to almost
313 6 years). As fibrosis can progress among HCM patients⁷, it could have influenced the results.
314 Exclusion of non-MRI patients could introduce a selection bias. The low number of events limits
315 our conclusions especially in those without germline P/LP variants. Further cohorts needed to
316 fully evaluate CH's impact on HCM.

317

318 **Conclusions**

319 The variability in the expression of the HCM phenotype could be explained by an interaction of
320 genetic and epigenetic regulators. This study showed that the CH prevalence among HCM

321 patients is higher than expected for a similar age. CH was associated with the presence of
322 fibrosis and with poorer outcomes. CH is a new paradigm in HCM, impacting the phenotype and
323 prognosis.

324

325 **REFERENCES**

- 326 1. Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and evaluation of hypertrophic
327 cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol*. 2022;79(4):372-389.
328 doi:10.1016/j.jacc.2021.12.002
- 329 2. Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on
330 diagnosis and management of hypertrophic cardiomyopathy: the task force for the
331 diagnosis and management of hypertrophic cardiomyopathy of the European Society of
332 Cardiology (ESC). *Eur Heart J*. 2014;35(39):2733-2779. doi:10.1093/eurheartj/ehu284
- 333 3. Maron BJ, Desai MY, Nishimura RA, et al. Management of hypertrophic cardiomyopathy:
334 JACC state-of-the-art review. *J Am Coll Cardiol*. 2022;79(4):390-414.
335 doi:10.1016/j.jacc.2021.11.021
- 336 4. Maron BJ, Haas TS, Goodman JS. Hypertrophic cardiomyopathy: One gene ... but many
337 phenotypes. *Am J Cardiol*. 2014;113(10):1772-1773. doi:10.1016/j.amjcard.2014.02.032
- 338 5. Rowin EJ, Maron BJ, Maron MS. The hypertrophic cardiomyopathy phenotype viewed
339 through the prism of multimodality imaging: clinical and etiologic implications. *JACC*
340 *Cardiovasc Imaging*. 2020;13(9):2002-2016. doi:10.1016/j.jcmg.2019.09.020
- 341 6. Finocchiaro G, Magavern E, Sinagra G, et al. Impact of demographic features, lifestyle,
342 and comorbidities on the clinical expression of hypertrophic cardiomyopathy. *J Am Heart*
343 *Assoc*. 2017;6(12):1-11. doi:10.1161/JAHA.117.007161
- 344 7. Habib M, Adler A, Fardfini K, et al. Progression of myocardial fibrosis in hypertrophic
345 cardiomyopathy: a cardiac magnetic resonance study. *JACC Cardiovasc Imaging*.
346 2021;14(5):947-958. doi:10.1016/j.jcmg.2020.09.037
- 347 8. Maron BABJ, Maron MS, Maron BABJ, Loscalzo J. Moving beyond the sarcomere to
348 explain heterogeneity in hypertrophic cardiomyopathy: JACC review topic of the week. *J*
349 *Am Coll Cardiol*. 2019;73(15):1978-1986. doi:10.1016/j.jacc.2019.01.061
- 350 9. Scolari FL, Abelson S, Brahmabhatt DH, et al. Clonal haematopoiesis is associated with
351 higher mortality in patients with cardiogenic shock. *Eur J Heart Fail*. 2022;24(9):1573-
352 1582. doi:10.1002/ejhf.2588
- 353 10. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic
354 cardiovascular disease. *N Engl J Med*. 2017;377(2):111-121.
355 doi:10.1056/NEJMoa1701719
- 356 11. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated
357 with adverse outcomes. *N Engl J Med*. 2014;371(26):2488-2498.
358 doi:10.1056/NEJMoa1408617

- 359 12. Dorsheimer L, Assmus B, Rasper T, et al. Association of mutations contributing to clonal
360 hematopoiesis with prognosis in chronic ischemic heart failure. *JAMA Cardiol.*
361 2019;4(1):25-33. doi:10.1001/jamacardio.2018.3965
- 362 13. Calvillo-Argüelles O, Jaiswal S, Shlush LI, et al. Connections between clonal
363 hematopoiesis, cardiovascular disease, and cancer: A review. *JAMA Cardiol.*
364 2019;4(4):380-387. doi:10.1001/JAMACARDIO.2019.0302
- 365 14. Wang Y, Sano S, Yura Y, et al. Tet2-mediated clonal hematopoiesis in nonconditioned
366 mice accelerates age-associated cardiac dysfunction. *JCI Insight.* 2020;5(6):e135204.
367 doi:10.1172/jci.insight.135204
- 368 15. Sano S, Oshima K, Wang Y, et al. TET2-mediated clonal hematopoiesis accelerates heart
369 failure through a mechanism involving the IL-1 β /NLRP3 inflammasome. *J Am Coll Cardiol.*
370 2018;71(8):875-886. doi:10.1016/j.jacc.2017.12.037
- 371 16. Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene
372 editing to assess the roles of TET2 and DNMT3A in clonal hematopoiesis and
373 cardiovascular disease. *Circ Res.* 2018;123(3):335-341.
374 doi:10.1161/CIRCRESAHA.118.313225
- 375 17. Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2
376 deficiency accelerates atherosclerosis development in mice. *Science.*
377 2017;355(6327):842-847. doi:10.1126/science.aag1381
- 378 18. Coats CJ, Heywood WE, Virasami A, et al. Proteomic analysis of the myocardium in
379 hypertrophic obstructive cardiomyopathy. *Circ Genom Precis Med.* 2018;11(12):e001974.
380 doi:10.1161/CIRCGEN.117.001974
- 381 19. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and
382 treatment of patients with hypertrophic cardiomyopathy. *Circulation.*
383 2020;142(25):e533-e557. doi:10.1161/CIR.0000000000000937
- 384 20. Hoss S, Habib M, Silver J, et al. Genetic testing for diagnosis of hypertrophic
385 cardiomyopathy mimics: yield and clinical significance. *Circ Genom Precis Med.*
386 2020;13(4):E002748. doi:10.1161/CIRCGEN.119.002748
- 387 21. de Marvao A, McGurk KA, Zheng SL, et al. Phenotypic expression and outcomes in
388 individuals with rare genetic variants of hypertrophic cardiomyopathy. *J Am Coll Cardiol.*
389 2021;78(11):1097-1110. doi:10.1016/j.jacc.2021.07.017
- 390 22. Scolari FL, Brahmabhatt DH, Abelson S, et al. Clonal hematopoiesis confers an increased
391 mortality risk in orthotopic heart transplant recipients. *Am J Transplant.* 2022;22(12).
392 doi:10.1111/ajt.17172

- 393 23. Ingles J, Burns C, Bagnall RD, et al. Nonfamilial hypertrophic cardiomyopathy. *Circ*
394 *Cardiovasc Genet.* 2017;10(2). doi:10.1161/CIRCGENETICS.116.001620
- 395 24. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical
396 manifestations, diagnosis, and therapy. *Circ Res.* 2017;121(7):749-770.
397 doi:10.1161/CIRCRESAHA.117.311059
- 398 25. Young AL, Challen GA, Birman BM, Druley TE. Clonal haematopoiesis harbouring AML-
399 associated mutations is ubiquitous in healthy adults. *Nat Commun.* 2016;7:12484.
400 doi:10.1038/ncomms12484
- 401 26. Assmus B, Cremer S, Kirschbaum K, et al. Clonal haematopoiesis in chronic ischaemic
402 heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
403 *Eur Heart J.* 2021;42(3):257-265. doi:10.1093/EURHEARTJ/EHAA845
- 404 27. Watson CJ, Papula AL, Poon GYP, et al. The evolutionary dynamics and fitness landscape
405 of clonal hematopoiesis. *Science.* 2020;367(6485):1449-1454.
406 doi:10.1126/science.aay9333
- 407 28. Mitchell E, Spencer Chapman M, Williams N, et al. Clonal dynamics of haematopoiesis
408 across the human lifespan. *Nature.* 2022;606(7913):343-350. doi:10.1038/s41586-022-
409 04786-y
- 410 29. Pascual-Figal DA, Bayes-Genis A, Díez-Díez M, et al. Clonal hematopoiesis and risk of
411 progression of heart failure with reduced left ventricular ejection fraction. *J Am Coll*
412 *Cardiol.* 2021;77(14):1747-1759. doi:10.1016/j.jacc.2021.02.028
- 413 30. Sano S, Wang Y, Ogawa H, et al. TP53-mediated therapy-related clonal hematopoiesis
414 contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-
415 mediated cytotoxic response. *JCI Insight.* 2021;6(13). doi:10.1172/jci.insight.146076
- 416 31. Sano S, Wang Y, Yura Y, et al. JAK2-V617F-Mediated clonal hematopoiesis accelerates
417 pathological remodeling in murine heart failure. *JACC Basic Transl Sci.* 2019;4(6):684-697.
418 doi:10.1016/j.jacbts.2019.05.013
- 419 32. Min KD, Polizio AH, Kour A, Thel MC, Walsh K. Experimental ASXL1-mediated clonal
420 hematopoiesis promotes inflammation and accelerates heart failure. *J Am Heart Assoc.*
421 2022;11(19). doi:10.1161/JAHA.122.026154
- 422 33. Bittencourt MI, Cader SA, Araújo DV, et al. Role of myocardial fibrosis in hypertrophic
423 cardiomyopathy: A systematic review and updated meta-analysis of risk markers for
424 sudden death. *Arq Bras Cardiol.* 2019;112(3):281-289. doi:10.5935/abc.20190045
- 425 34. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ. Prospective
426 prognostic assessment of blood pressure response during exercise in patients with

427 hypertrophic cardiomyopathy. *Circulation*. 1997;96(9):2987-2991.
428 doi:10.1161/01.CIR.96.9.2987

429 35. Cremer S, Kirschbaum K, Berkowitsch A, et al. Multiple somatic mutations for clonal
430 hematopoiesis are associated with increased mortality in patients with chronic heart
431 failure. *Circ Genom Precis Med*. 2020;13(4):340-342. doi:10.1161/CIRCGEN.120.003003

432 36. Shimada YJ, Raita Y, Liang LW, et al. Comprehensive proteomics profiling reveals
433 circulating biomarkers of hypertrophic cardiomyopathy. *Circ Heart Fail*.
434 2021;14(7):E007849. doi:10.1161/CIRCHEARTFAILURE.120.007849

435

436

437 **FIGURES LEGENDS**

438 **Central figure. Survival in HCM according to somatic CH-related mutations and sarcomeric**
439 **germline P/LP variants.**

440 HCM patients with CH and germline sarcomeric gene LP/P variants show the worse prognosis in
441 comparison to HCM patients without CH or without germline sarcomeric gene LP/P variants,
442 highlighting that the presence of both risk factors warrants concern.

443 (CH, clonal haematopoiesis ; G, germline sarcomeric gene P/LP variants; LP, likely pathogenic; P,
444 pathogenic).

445

446 **Figure 1. Somatic mutations related to CH in patients with HCM.**

447 Panel A shows the number of mutations in the most common affected genes in the cohort..

448 Panel B shows the number of mutations per patients in those with clonal haematopoiesis .CH.

449 Panel C shows the number of patients with CH according to the decade of the assessment. (CH,
450 clonal haematopoiesis ; HCM, hypertrophic cardiomyopathy).

451

452 **Figure 2. Survival in patients with HCM stratified according to CH.**

453 Panel A shows the survival according to the presence of CH among HCM patients. Panel B

454 shows the survival according to the presence of clonal haematopoiesis in the *DNMT3A*, *TET2*,

455 and *ASXL1* genes among HCM patients. Panel C shows the survival according to the presence of

456 clonal haematopoiesis among HCM patients with germline P/LP sarcomeric variants. Panel D

457 shows the survival according to the presence of clonal haematopoiesis in the *DNMT3A*, *TET2*,
458 and *ASXL1* genes among HCM patients with germline P/LP sarcomeric variants. (CH, clonal
459 haematopoiesis; HCM, hypertrophic cardiomyopathy; P/LP, pathogenic/likely pathogenic).

460

461 **Figure 3. Troponin I, cytokines and chemokines levels among HCM with germline sarcomeric**
462 **P/LP variant according to CH.** (CH, clonal haematopoiesis; HCM, hypertrophic cardiomyopathy,
463 P/LP, pathogenic/likely pathogenic).

464 HCM patients with germline sarcomeric genes LP/P variants show upregulated levels of
465 Troponin I, cytokines and chemokines.

466

Table 1. Overall characteristics of the HCM cohort and between those with or without CH.				
	All (N=799)	No CH (N=616)	CH (N=183)	P
Age, mean (SD), years	55.7 (14.6)	55.3 (14.5)	57.2 (14.8)	0.126
Age at diagnosis, mean (SD), years	47.8 (15.8)	47.3 (15.6)	49.6 (16.3)	0.089
Male sex, No. (%)	547 (68.5)	424 (68.8)	123 (67.2)	0.679
Body mass index ¹ , mean (SD), kg/m ²	29.0 (6.9)	29.0 (7.1)	29.2 (6.2)	0.647
Hypertension, No. (%)	315 (39.4)	233 (37.8)	82 (44.8)	0.093
Diabetes, No. (%)	104 (13.0)	78 (12.6)	26 (14.2)	0.863
Prior/current smoker, No. (%)	155 (19.3)	119 (19.3)	36 (19.6)	0.637
Coronary artery disease, No. (%)	73 (9.1)	61 (9.9)	12 (6.5)	0.166
Atrial fibrillation, No. (%)	143 (17.8)	107 (17.3)	36 (19.6)	0.493
Genetic testing, No. (%)	712 (89.1)	554 (89.9)	158 (86.3)	0.170
Germline pathogenic/likely pathogenic sarcomeric variant, No. (%)	206 (25.8)	169 (30.5)	37 (23.4)	0.083
<i>MYH7</i> , No. (%)	53 (25.7)	43 (25.6)	10 (27.0)	0.664
<i>MYBPC3</i> , No. (%)	127 (61.6)	106 (63.1)	21 (56.8)	
Other, No. (%)	26 (12.6)	20 (11.8)	6 (16.2)	
Family history of HCM, No. (%)	251 (31.4)	194 (31.5)	57 (31.1)	0.087
Family history of SCD, No. (%)	37 (4.6)	26 (4.2)	11 (6.0)	0.048

Implantable cardioverter defibrillator, No. (%)	111 (13.9)	89 (14.4)	22 (12.0)	0.405
Pacemaker, No. (%)	13 (1.6)	6 (1.0)	7 (3.8)	0.007
NYHA II-IV, No. (%)	235 (29.4)	182 (29.5)	53 (28.9)	0.803
Beta-blocker, No. (%)	421 (52.7)	321 (52.1)	100 (54.6)	0.547
Non-dihydropyridine calcium channel blocker, No. (%)	116 (14.5)	77 (12.5)	39 (21.3)	0.003
Disopyramide, No (%)	67 (8.4)	51 (8.3)	16 (8.7)	0.842
Diuretic, No (%)	81 (10.1)	59 (9.5)	22 (12.0)	0.303
Septal reduction therapy, No. (%)	76 (9.5)	53 (8.6)	23 (12.5)	0.130
Abbreviations: CH, clonal haematopoiesis; HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death				
¹ Body mass index calculated as weigh (kg)/height ² (m)				

Table 2. Clinical phenotype and outcomes according to CH and specific CH-related genes among HCM patients with germline P/LP sarcomeric variants


	All-CH			<i>DNMT3A, TET2, ASXL1</i>		
	No CH (N=169)	CH (N=37)	p	No CH (N=169)	CH (N=23)	p
<i>Echocardiogram</i>						
MLVWT, mean (SD), mm	17.3 (4.6)	17.6 (5.1)	0.765	17.4 (4.7)	17.5 (4.9)	0.852
LA diameter, mm	3.9 (1.2)	3.8 (1.1)	0.651	3.9 (1.2)	3.7 (1.4)	0.643
LAVi, ml/m ²	38.5 (30.8)	41.3 (20.7)	0.599	38.5 (30.8)	35.6 (20.3)	0.655
LV EF, %	58.2 (15.3)	62.4 (6.2)	0.106	58.2 (15.3)	63.0 (7.3)	0.149
LVOT maximal gradient, mm Hg	17.2 (26.6)	22.5 (40.3)	0.316	17.2 (26.6)	22.6 (43.5)	0.402
SAM, No. (%)	76 (45.0)	21 (56.8)	0.193	76 (45.0)	13 (56.5)	0.297
Moderate-severe MR, No. (%)	7 (4.1)	1 (2.7)	0.681	7 (4.1)	0	0.320
<i>Cardiac MRI</i>						

LV mass, g	137.3 (52.9)	143.1 (61.4)	0.601	137.3 (52.9)	142.3 (65.5)	0.703
LV mass index, g/m ²	72.1 (25.5)	74.7 (27.2)	0.622	72.1 (25.5)	73.1 (30.2)	0.876
MLVWT, mm	18.9 (6.4)	19.2 (5.6)	0.814	18.9 (6.4)	19.0 (5.8)	0.989
LV EF, %	60.8 (8.3)	62.1 (6.2)	0.390	60.8 (8.3)	61.1 (5.8)	0.884
LGE, No (%)	134 (79.3)	27 (73.0)	0.400	134 (79.3)	17 (73.9)	0.555
LGE >15%, No (%)	26 (17.7)	11 (33.3)	0.044	26 (17.7)	7 (35.0)	0.068
LV mass % of LGE ¹ , %	12.2 (7.7-17.6)	15.6 (10.4- 24.6)	0.068	12.2 (7.7-17.8)	21.2 (13.7- 41.8)	0.017
Apical Aneurysm, No (%)	1 (0.6)	1 (2.7)	0.145	1 (0.6)	0	0.711
Syncope, No (%)	6 (3.6)	3 (8.1)	0.219	6 (3.6)	2 (8.7)	0.247
ABPR at exercise, No. (%) (85/15)	25 (29.8)	10 (62.5)	0.012	25 (29.8)	8 (66.7)	0.012
NVST, No. (%) (145/21)	52 (37.7)	11 (39.3)	0.873	52 (37.7)	7 (41.2)	0.779
<i>Outcomes</i>						
Stroke, No. (%)	2 (1.2)	2 (5.4)	0.092	2 (1.2)	1 (4.3)	0.251
Appropriate ICD shock, No. (%)	2 (1.2)	0	0.506	2 (1.1)	0	0.614

Cardiac arrest, No. (%)	0	0	n/a	0	0	n/a
Death or orthotopic heart transplant, No. (%)	2 (1.2)	3 (8.1)	0.013	2 (1.2)	3 (13.0)	<0.0001
MACE, No. (%)	5 (3.0)	5 (13.5)	0.008	5 (3.0)	4 (17.4)	.003


¹Quantified LGE>5%.



ABPR, abnormal blood pressure response; EF, ejection fraction; LA, left atrium diameter; LAVi, left atrium volume index; ICD, implantable cardioverter defibrillator; LGE, late gadolinium enhancement; LV, left ventricle; LVOT, left ventricular outflow tract; MACE, major cardiovascular events; MLVWT, maximal left ventricular wall thickness; MR, mitral regurgitation; MRI, magnetic resonance imaging; NSVT, non-sustained ventricular tachycardia; P/LP, pathogenic/likely pathogenic; SAM, systolic anterior motion;



No. at risk

	0	365	730	1095	1460	1825
CH-/G-	344	256	154	56	25	4
CH-/G+	112	86	53	14	6	0
CH+/G-	158	117	62	26	6	1
CH+/G+	37	25	11	6	2	0



A**B****C**